Companies / Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc.
Nasdaq: AVTXCIK 1534120WAYNE, PA
Financials · FY2025
Ownership
53.6M shares outstanding · as of Aug 3, 2026
Ownership
| Insiders | 0.23% | 122,234 |
| 10%+ / strategic | 14.04% | 7,530,926 |
| Institutions | 41.42% | 22,213,948 |
| Public float | 44.31% | 23,762,881 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 13
View all →| Insider | % of shares | Shares |
|---|---|---|
Neil Garry ArthurCEOChief Executive Officer · Director | 0.17% | 90,114 |
Sullivan Christopher RyanFormerChief Financial Officer | 0.06% | 33,297 |
Chan MitchellDirector | 0.01% | 6,333 |
Kantoff AaronDirector | 0.01% | 6,333 |
Kaplan GillaDirector | 0.01% | 6,333 |
Truex SamanthaDirector | 0.01% | 6,333 |
Doyle MittieChief Medical Officer | <0.01% | 3,622 |
Goldman JonathanDirector | <0.01% | 3,166 |
Boyd TaylorChief Business Officer | — | — |
Jain RitaDirector | — | — |
Institutional holders 89
View all →| Holder | Value | % of shares |
|---|---|---|
| $80.68M | 8.14% | |
| $53.39M | 5.39% | |
| $24.38M | 3.04% | |
| $22.43M | 2.30% | |
| $19.09M | 1.96% | |
| $16.01M | 1.64% | |
| $14.60M | 1.50% | |
| $12.75M | 1.59% | |
| $12.47M | 1.56% | |
| $11.40M | 1.17% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $75.32M | +4.1M +1407.59% | 4,365,553 8.14% of shares | high |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $51.93M | +2.8M +3545.60% | 2,889,287 5.39% of shares | high |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Trim | Common stock | $-10.63M | -712K -59.98% | 475,165 0.89% of shares | medium |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Trim | Common stock | $-5.65M | -378K -74.56% | 129,136 0.24% of shares | medium |
| Q1 2026 as of | Adage Capital Partners Gp, L.L.C. 13F manager | Add | Common stock | $4.54M | +304K +55.27% | 854,000 1.59% of shares | low |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | Add | Common stock | $4.36M | +292K +66.53% | 731,586 1.36% of shares | low |
| Q1 2026 as of | Bvf INC/IL 13F manager | Add | Common stock | $4.14M | +278K +20.48% | 1,632,845 3.04% of shares | low |
| Q1 2026 as of | BNP Paribas Financial Markets 13F manager | Add | Common stock | $3.36M | +225K +113.80% | 422,781 0.79% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| Fmr LLC | Passive13G/A | — |
| State Street Corporation | Passive13G | — |
| Orbimed Advisors LLC | Passive13G/A | — |
| Balyasny Asset Management L.P. | Passive13G/A | — |
| Millennium Management LLC | Passive13G | — |
| Millennium Management LLC | Passive13G | — |
| Millennium Management LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| AVTX | — | 05338F306 |